UnityPoint Health - Des Moines

Lung Cancer Research Studies

Non-Small Cell

AFT-09: Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition with Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients with Chemotherapy naive stage IV Non-small Cell Lung Cancer

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) (screening trial for A081105, E4512 and EA5142)

A081105:   

Randomized Study of Erlotinib vs Observation Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) (must be enrolled on screening trial A151216

 E4512:

A Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (must be enrolled on screening trial A151216)

EA5142:

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (must be enrolled on screening trial A151216)

BR001:  A Phase I Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

LU002: Comparing Standard Treatment Alone to Radiation Therapy with Standard Treatment for Patients with Limited Metastatic Non-Small Cell Lung Cancer

S1400: Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer

S1507: Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive Non-Small Cell Lung Cancer and Progressive Disease Following One or Two Prior Systemic Therapies

Small Cell

AFT-17: A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-line Treatment of Patients with Small Cell Lung Cancer

CC003: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer